Research Study

A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis
Principal Investigator 
Robert Carruthers

Overview

Body Locations and Systems 
Multiple Sclerosis
ClinicalTrials.gov# 
NCT02792218
Status 
Recruiting
Study Start/End 
Mar 22, 2017 to Feb 1, 2020
Locations 
UBC Hospital, Vancouver General Hospital
Name/Title 
Karina Grigore, Research Coordinator
Phone 
604-827-1892
Email Address 
karina.grigore@ubc.ca
Purpose of Study 

 

To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis.

Eligibility 

Visit ClinicalTrials.gov for more information. 

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.